Elevation Oncology (ELEV) investor relations material

Executive summary

• Net loss of $14.2 million for Q1 2025, up from $10.7 million in Q1 2024, with an accumulated deficit of $254.7 million as of March 31, 2025.

• Discontinued EO-3021 development and implemented a 70% workforce reduction to focus resources and evaluate strategic alternatives.

• Focus shifted to advancing EO-1022, a HER3-targeting ADC, with IND filing expected in 2026 and promising preclinical data presented at AACR 2025.

• Workforce reduction resulted in $3.4 million in restructuring charges.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $80.7 million as of March 31, 2025; expected to be $30M–$35M after loan prepayment and restructuring.

• Research and development expenses were $6.9 million, up from $6.0 million year-over-year, mainly due to EO-1022 advancement.

• General and administrative expenses were $4.0 million, slightly higher than $3.9 million in Q1 2024.

• Net loss per share: $(0.24) for Q1 2025 vs. $(0.21) for Q1 2024.

• Long-term debt was $31.3 million at quarter-end, fully prepaid in May 2025.

Outlook and guidance

• Cash runway expected to fund operations into the second half of 2026, but additional capital will be needed for further development and commercialization.

• IND filing for EO-1022 planned for 2026, with continued investment in preclinical and IND-enabling activities.

• Company is evaluating strategic alternatives, including potential mergers, asset sales, or licensing deals.